Tiotropium for Stable Chronic Obstructive Pulmonary Disease: A Meta-analysis

Overview

Journal Thorax

Date 2006 Jul 18

PMID 16844726

Citations 56

Authors

R G Barr

J Bourbeau

C A Camargo

F S F Ram

Affiliations

Soon will be listed here.

Abstract

Background: A systematic review was undertaken to evaluate the efficacy of tiotropium, a long acting anticholinergic drug, on clinical events, symptom scales, pulmonary function, and adverse events in stable chronic obstructive pulmonary disease (COPD).

Methods: A systematic search was made of the Cochrane trials database, MEDLINE, EMBASE, CINAHL, and a hand search of 20 respiratory journals. Missing data were obtained from authors and the manufacturer. Randomised controlled trials of > or =12 weeks' duration comparing tiotropium with placebo, ipratropium bromide, or long acting beta2 agonists (LABA) were reviewed. Studies were pooled to yield odds ratios (OR) or weighted mean differences with 95% confidence intervals (CI).

Results: Nine trials (8002 patients) met the inclusion criteria. Tiotropium reduced the odds of a COPD exacerbation (OR 0.73; 95% CI 0.66 to 0.81) and related hospitalisation (OR 0.68; 95% CI 0.54 to 0.84) but not pulmonary (OR 0.50; 95% CI 0.19 to 1.29) or all-cause (OR 0.96; 95% CI 0.63 to 1.47) mortality compared with placebo and ipratropium. Reductions in exacerbations and hospitalisations compared with LABA were not statistically significant. Similar patterns were evident for quality of life and symptom scales. Tiotropium yielded greater increases in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) from baseline to 6-12 months than did placebo, ipratropium, and LABA. Decline in FEV1 over 1 year was 30 ml (95% CI 7 to 53) slower with tiotropium than with placebo and ipratropium (data were not available for LABA). Reports of dry mouth and urinary tract infections were increased with tiotropium.

Conclusions: Tiotropium reduced COPD exacerbations and related hospitalisations, improved quality of life and symptoms, and may have slowed the decline in FEV1. Long term trials are warranted to evaluate the effects of tiotropium on decline in FEV1 and to clarify its role compared with LABA.

Citing Articles

Evaluation of a Ureteral Stent Removal Protocol in Adult Kidney Transplant Recipients.

Krzos P, Nguyen C, Kane B, Krishnamoorthy S, Kristof T, Reynolds L Open Forum Infect Dis. 2024; 11(9):ofae510.

PMID: 39310271 PMC: 11414405. DOI: 10.1093/ofid/ofae510.

Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists.

Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A Int J Chron Obstruct Pulmon Dis. 2022; 17:1715-1733.

PMID: 35941901 PMC: 9356604. DOI: 10.2147/COPD.S363997.

Safety of tiotropium in patients with asthma.

Dusser D, Ducharme F Ther Adv Respir Dis. 2019; 13:1753466618824010.

PMID: 30795731 PMC: 6391545. DOI: 10.1177/1753466618824010.

The Impact of Sepsis on the Outcomes of COPD Patients: A Population-Based Cohort Study.

Chen C, Lai C, Wang Y, Wang C, Wang H, Yu C J Clin Med. 2018; 7(11).

PMID: 30373237 PMC: 6262552. DOI: 10.3390/jcm7110393.

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD.

Kang J, Kim K, Lee J, Kim E, Kim T, Yoo K Int J Chron Obstruct Pulmon Dis. 2017; 12:3557-3565.

PMID: 29263660 PMC: 5732547. DOI: 10.2147/COPD.S151909.

References

Anthonisen N, Connett J, Kiley J, Altose M, Bailey W, Buist A . Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994; 272(19):1497-505. View

MAESEN F, Smeets J, Sledsens T, Wald F, CORNELISSEN P . Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J. 1995; 8(9):1506-13. View

Redelmeier D, Goldstein R, Min S, Hyland R . Spirometry and dyspnea in patients with COPD. When small differences mean little. Chest. 1996; 109(5):1163-8. DOI: 10.1378/chest.109.5.1163. View

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

OConnor B, Towse L, Barnes P . Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med. 1996; 154(4 Pt 1):876-80. DOI: 10.1164/ajrccm.154.4.8887578. View

Murray C, Lopez A . Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997; 349(9064):1498-504. DOI: 10.1016/S0140-6736(96)07492-2. View

Disse B, Speck G, ROMINGER K, Witek Jr T, Hammer R . Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999; 64(6-7):457-64. DOI: 10.1016/s0024-3205(98)00588-8. View

Mahler D, Donohue J, BARBEE R, Goldman M, Gross N, Wisniewski M . Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999; 115(4):957-65. DOI: 10.1378/chest.115.4.957. View

Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, Di Marco F . The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med. 2004; 98(12):1214-21. DOI: 10.1016/j.rmed.2004.05.003. View

10.

Anzueto A, Tashkin D, Menjoge S, Kesten S . One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther. 2005; 18(2):75-81. DOI: 10.1016/j.pupt.2004.10.003. View

11.

Terzano C, Petroianni A, Ricci A, DAntoni L, Allegra L . Early protective effects of tiotropium bromide in patients with airways hyperresponsiveness. Eur Rev Med Pharmacol Sci. 2005; 8(6):259-64. View

12.

Casaburi R, Kukafka D, Cooper C, Witek Jr T, Kesten S . Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005; 127(3):809-17. DOI: 10.1378/chest.127.3.809. View

13.

Baloira Villar A, Vilarino Pombo C . [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease]. Arch Bronconeumol. 2005; 41(3):130-4. DOI: 10.1016/s1579-2129(06)60413-8. View

14.

Cazzola M, Noschese P, Salzillo A, De Giglio C, DAmato G, Matera M . Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med. 2005; 99(5):524-8. DOI: 10.1016/j.rmed.2004.10.004. View

15.

Barr R, Bourbeau J, Camargo C, Ram F . Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; (2):CD002876. PMC: 6544812. DOI: 10.1002/14651858.CD002876.pub2. View

16.

van Noord J, Aumann J, Janssens E, Smeets J, Verhaert J, Disse B . Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005; 26(2):214-22. DOI: 10.1183/09031936.05.00140404. View

17.

Niewoehner D, Rice K, Cote C, Paulson D, Cooper Jr J, Korducki L . Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005; 143(5):317-26. DOI: 10.7326/0003-4819-143-5-200509060-00007. View

18.

Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba F, Richter K . Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005; 128(3):1168-78. DOI: 10.1378/chest.128.3.1168. View

19.

Briggs Jr D, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C . Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005; 18(6):397-404. DOI: 10.1016/j.pupt.2005.02.013. View

20.

Dusser D, Bravo M, Iacono P . The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J. 2006; 27(3):547-55. DOI: 10.1183/09031936.06.00062705. View